Jim Simons Avidity Biosciences, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 377,400 shares of RNA stock, worth $17.8 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

377,400

Holding current value

$17.8 Million

% of portfolio

0.03%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$22.73 - $40.85 $8.58 Million - $15.4 Million	377,400 New	377,400 $15.4 Million
Q4 2023 Feb 13, 2024	BUY	$4.87 - $9.37 $564,433 - $1.09 Million	115,900 Added 104.6%	226,700 $2.05 Million
Q3 2023 Nov 14, 2023	BUY	$6.3 - $11.35 $282,870 - $509,615	44,900 Added 68.13%	110,800 $707,000
Q2 2023 Aug 11, 2023	SELL	$10.62 - $17.34 $3.28 Million - $5.36 Million	-309,200 Reduced 82.43%	65,900 $731,000
Q1 2023 May 12, 2023	BUY	$15.35 - $25.65 $3.2 Million - $5.35 Million	208,500 Added 125.15%	375,100 $5.76 Million
Q4 2022 Feb 13, 2023	BUY	$10.06 - $22.66 $428,556 - $965,316	42,600 Added 34.35%	166,600 $3.7 Million
Q3 2022 Nov 14, 2022	BUY	$15.46 - $23.43 $242,722 - $367,851	15,700 Added 14.5%	124,000 $2.03 Million
Q2 2022 Aug 12, 2022	BUY	$11.18 - $20.5 $781,482 - $1.43 Million	69,900 Added 182.03%	108,300 $1.57 Million
Q1 2022 May 13, 2022	BUY	$14.2 - $23.78 $380,560 - $637,304	26,800 Added 231.03%	38,400 $709,000
Q4 2021 Feb 11, 2022	BUY	$20.4 - $28.66 $236,639 - $332,456	11,600 New	11,600 $276,000

Others Institutions Holding RNA

# of Institutions

221

Shares Held

95.9M

Call Options Held

171K

Put Options Held

196K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $2.46B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account